2025
Outcomes after en bloc resection with sacrectomy of advanced colorectal carcinomas that invade the sacrum: a multiinstitutional descriptive series.
Pieters T, Hersh A, Elsamadicy A, Pennington Z, Santangelo G, Najjar S, Hung B, Ber R, Atallah C, Efron J, Gearhart S, Safar B, Wolinsky J, Sciubba D, Lo S. Outcomes after en bloc resection with sacrectomy of advanced colorectal carcinomas that invade the sacrum: a multiinstitutional descriptive series. Journal Of Neurosurgery Spine 2025, 1-7. PMID: 40053935, DOI: 10.3171/2024.10.spine24391.Peer-Reviewed Original ResearchInvasive colorectal carcinomaBloc resectionColorectal carcinomaMedian OSR0 resectionLocal controlOverall survivalMedian local progression-free survivalLocal progression-free survivalPresence of distant metastasesResection of colorectal carcinomaAssociated with poor OSGross-total resectionProgression-free survivalAdvanced colorectal carcinomaSacral invasionTumor morphometryNegative marginsDistant metastasisPoor OSSacral resectionPalliative intentSurgical excisionPerioperative outcomesLevel of osteotomy
2024
Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Shah R, Wilkins S, Safranek C, Shah H, Brophy C, Mehra S. Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head & Neck Surgery 2024, 150: 1105-1112. PMID: 39418066, PMCID: PMC11581730, DOI: 10.1001/jamaoto.2024.3237.Peer-Reviewed Original ResearchHPV-positive oropharyngeal squamous cell carcinomaOropharyngeal squamous cell carcinomaSquamous cell carcinomaDistant metastasisDisease recurrenceCell carcinomaRecurrence detectionHuman papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomaCohort studyMethod of recurrence detectionSurveillance strategiesSurveillance imaging strategiesLocation of recurrencePatterns of recurrenceFollow-up timeElectronic medical record reviewOptimal surveillance strategyPercentage of patientsRetrospective cohort studyIncidence of DMTertiary care hospitalDiagnosis to deathMedical record reviewRecurrence cohortRegional recurrenceModeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencingEvaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Husain Z, Rybkin A, Lee V, Young M, Eskander A, Burtness B, Park H. Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e759-e760. DOI: 10.1016/j.ijrobp.2024.07.1668.Peer-Reviewed Original ResearchLymphovascular space invasionOral cavity carcinomaOverall survivalIntermediate-riskHigh riskT3/4 diseaseDistant metastasisN stageStandard riskPrediction of distant metastasisGrade 3 tumorsMedian follow-upNational Cancer DatabasePathological risk factorsOral cavity cancerKaplan-Meier methodLog-rank testSubsets of patientsHospital-based cohortClinical trial stratificationHigh-volume hospitalsT3/4 tumorsMedian followSurgical resectionIndividualized treatment selectionA nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer
Liu J, Sun R, Cai K, Xu Y, Yuan W. A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer. Scientific Reports 2024, 14: 15391. PMID: 38965325, PMCID: PMC11224267, DOI: 10.1038/s41598-024-65307-7.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioPrognostic nutritional indexPlatelet-to-lymphocyte ratioSystemic immune-inflammatory indexLymphocyte to monocyte ratioMultivariate logistic regression analysisDistant metastasisLogistic regression analysisLymphocyte ratioReceiver operating characteristicGastric cancerValidation cohortPredictive factorsRisk factors of distant metastasisDistant metastasis of gastric cancerNutritional indexImmune-inflammatory indexClinical practiceNomogram's predictive performanceDecision curve analysisGastric cancer patientsMetastasis of gastric cancerEfficient nomogramRegression analysisMonocyte ratioLymph node metastasis prediction with non-small cell lung cancer histopathology imaging.
Lee V, King A, Sritharan D, Moore N, Chadha S, Maresca R, Hager T, Aneja S. Lymph node metastasis prediction with non-small cell lung cancer histopathology imaging. Journal Of Clinical Oncology 2024, 42: 8063-8063. DOI: 10.1200/jco.2024.42.16_suppl.8063.Peer-Reviewed Original ResearchNon-small cell lung cancerLymph nodal metastasisNational Lung Screening TrialLymph node metastasisNodal metastasisNode metastasisEndobronchial ultrasound-guided transbronchial needle aspirationUltrasound-guided transbronchial needle aspirationTreatment strategy formulationTransbronchial needle aspirationCell lung cancerDistant metastasis statusLymph node metastasis predictionPrimary tumor dataHematoxylin and eosin (H&EInvasive diagnostic techniquesInfluence clinical decisionsN0 diseaseN3 diseaseEosin (H&EPrimary resectionDistant metastasisPET-CTNeedle aspirationCT scanSurrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx
Gharzai L, Morris E, Nguyen-Tan P, Rosenthal D, Gillison M, Harari P, Garden A, Zanotti K, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e14. DOI: 10.1016/j.ijrobp.2024.01.035.Peer-Reviewed Original ResearchLocoregional progression-free survivalProgression-free survivalP16-positive oropharyngeal cancerOverall survivalOropharyngeal cancerIncreasing incidence of HPV-related cancersIncidence of HPV-related cancersP16-positive squamous cell carcinomaOptimal treatment paradigmMedian follow-upHPV-related cancersSquamous cell carcinomaMulticenter randomized trialClinical trial endpointsLocoregional progressionDistant metastasisLocal progressionCell carcinomaDefinitive treatmentTreatment paradigmDMFSFollow-upRandomized trialsIncreased incidenceTreatment effectsSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual patient data meta-analysisMedian follow-upPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData meta-analysisLocoregional progressionNational Cancer InstituteDistant metastasisChapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Colorectal Carcinoma With Sarcomatoid Components
Golconda U, McHugh K, Allende D, Collins K, Henn P, Lacambra M, Bejarano P, Groisman G, Loughrey M, Monappa V, Zhang X, Hornick J, Gonzalez R. Colorectal Carcinoma With Sarcomatoid Components. The American Journal Of Surgical Pathology 2023, 48: 465-474. PMID: 38155543, DOI: 10.1097/pas.0000000000002172.Peer-Reviewed Original ResearchConceptsSarcomatoid componentColorectal carcinomaUndifferentiated carcinomaTumor-infiltrating lymphocytesNodal metastasisAbdominal painDistant metastasisRare subtypeSMARCA4 lossTumor buddingHeterologous elementsRepair protein expressionRectosigmoid regionSpindle cellsGastrointestinal bleedingKeratin-positivePoor prognosisFollow-upCarcinomaMismatch repair protein expressionMolecular testingAdvanced stageTumorLoss of mismatch repair protein expressionProtein expressionEndoscopic Ultrasound in Cancer Staging
Aslanian H, Muniraj T, Nagar A, Parsons D. Endoscopic Ultrasound in Cancer Staging. Gastrointestinal Endoscopy Clinics Of North America 2023, 34: 37-49. PMID: 37973230, DOI: 10.1016/j.giec.2023.09.009.Peer-Reviewed Original ResearchConcurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence functionPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinomaMammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
Beitsch P, Pellicane J, Pusztai L, Baron P, Cobain E, Murray M, Ashikari A, Kelemen P, Mislowsky A, Barone J, Cowan K, Layeequr Rahman R, Dooley W, Menicucci A, Finn C, Audeh M, Whitworth P. MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. Journal Of Clinical Oncology 2023, 41: 521-521. DOI: 10.1200/jco.2023.41.16_suppl.521.Peer-Reviewed Original ResearchDistant metastasis-free survivalPathological complete responseNeoadjuvant chemotherapyHigh riskGrade 3 tumorsLymph node statusObservational prospective studyHigh-risk tumorsKaplan-Meier analysisStage breast cancerLog-rank testPrediction of chemosensitivityESBC patientsMammaPrint testSYMPHONY trialsFree survivalNeoadjuvant therapyClinicopathologic subtypesComplete responseDistant metastasisImmune therapyMeier analysisRisk tumorsNode statusProspective studyGrading system for medullary thyroid carcinoma; an institutional experience
Podany P, Meiklejohn K, Garritano J, Holt E, Barbieri A, Prasad M, Gilani S. Grading system for medullary thyroid carcinoma; an institutional experience. Annals Of Diagnostic Pathology 2023, 64: 152112. PMID: 36736129, DOI: 10.1016/j.anndiagpath.2023.152112.Peer-Reviewed Original ResearchConceptsMedullary thyroid carcinomaTwo-tier grading systemDistant metastasisNuclear pleomorphismGrading systemNodal diseaseOverall survivalVascular invasionMTC casesThyroid carcinomaMedullary thyroid carcinoma casesMultivariate Cox regressionThyroid carcinoma casesCohort of casesRisk stratificationCox regressionTumor gradePathology reportsCarcinoma casesInstitutional experienceThyroid malignancyTumor fibrosisHG groupProminent nucleoliRare typeSignificance of Myoepithelial Cell Layer in Breast Ductal Carcinoma in situ With Papillary Architecture With and Without Associated Invasive Carcinoma
Golestani R, Singh K, Karam P, Pinto M, Liang Y, Orsaria M, Harigopal M. Significance of Myoepithelial Cell Layer in Breast Ductal Carcinoma in situ With Papillary Architecture With and Without Associated Invasive Carcinoma. Clinical Breast Cancer 2023, 23: 91-100. DOI: 10.1016/j.clbc.2022.09.006.Peer-Reviewed Original ResearchSolid papillary carcinomaPapillary DCISInvasive carcinomaMyoepithelial cellsPapillary architecturePapillary carcinomaConventional invasive carcinomaFoci of DCISPapillary breast lesionsAssociated invasive carcinomaBreast ductal carcinomaME cellsMyoepithelial cell layerCell layerMedian followDistant metastasisHistologic evidenceDuctal carcinomaME cell layersPathology databasePapillary componentRetrospective searchResults MajorityCarcinomaDCIS
2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibrationYES1 Is a Druggable Oncogenic Target in SCLC
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. YES1 Is a Druggable Oncogenic Target in SCLC. Journal Of Thoracic Oncology 2022, 17: 1387-1403. PMID: 35988891, DOI: 10.1016/j.jtho.2022.08.002.Peer-Reviewed Original ResearchConceptsSubpopulation of patientsOncogenic targetsPatient-derived xenograftsMarked antitumor activityGain/amplificationPlasma-derived exosomesDistant metastasisIndependent predictorsTargetable oncogenesPoor prognosisAggressive subtypeClinical managementLung cancerPharmacologic blockadeTumor regressionMouse modelTumor growthPlasma exosomesMolecular subgroupsPharmacologic inhibitionMetastasisAntitumor activityFunctional experimentsOrganoid modelsClinical samplesChondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB)
Ottesen TD, Shultz BN, Munger AM, Amick M, Toombs CS, Friedaender GE, Grauer JN. Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB). PLOS ONE 2022, 17: e0268215. PMID: 35901087, PMCID: PMC9333210, DOI: 10.1371/journal.pone.0268215.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseLong-term survivalMultivariate Cox analysisDistant metastasisSurgical treatmentChondrosarcoma patientsCox analysisCancer DatabaseLong-term survival dataKaplan-Meier survival curvesKaplan-Meier survival analysisPrimary osseous tumorsMainstay of treatmentExtent of diseasePoor prognostic factorPrimary tumor siteAge categoriesLikelihood of deathAxial involvementPatient characteristicsWorse survivalPrognostic factorsSurgical excisionMale sexOsseous tumorsCirculating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Knape C, Feger U, Marsico G, Howarth K, Winer EP, Lin NU, Parsons HA. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal Of Clinical Oncology 2022, 40: 2408-2419. PMID: 35658506, PMCID: PMC9467679, DOI: 10.1200/jco.22.00908.Peer-Reviewed Original ResearchConceptsMinimal residual diseaseWhole-exome sequencingClinical recurrenceMetastatic recurrenceBreast cancerEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerTumor tissueHigh-risk stage IIReceptor-positive breast cancerTumor DNAHuman epidermal growth factor receptorDistant metastatic recurrenceHormone receptor positiveMRD-positive patientsPlasma samplesTime of consentPrimary tumor tissuesSufficient tumor tissueEpidermal growth factor receptorAdjuvant settingGrowth factor receptorLocal recurrenceClinical outcomesDistant metastasis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply